

IN THE CLAIMS:

Please cancel claims 3, 4, 6 to 8, 13, 15 to 18, 21, 23, 29, 32 and 40 without prejudice.

Please amend the claims and add new claim 43 as follows:

1. (Currently Amended) A method of preventing the formation of inhibitory antibodies to ~~a blood coagulation protein~~ Factor IX delivered to a mammal by way of ~~gene therapy~~ an adeno-associated viral vector, wherein said mammal has a genetic defect which can result in generation of inhibitory antibodies to ~~a blood coagulation protein~~ Factor IX, said method comprising intravenously or intraperitoneally administering to said mammal cyclophosphamide prior to or simultaneously with said ~~gene therapy~~ adeno-associated viral vector delivery before formation of said inhibitory antibodies, the delivered ~~blood coagulation protein~~ Factor IX being from the same species as said mammal.
2. (Previously Presented) The method of claim 1, wherein said mammal and gene are human.
- 3.-23. (Canceled)
24. (Currently Amended) The method of claim 1, wherein said mammal has no detectable endogenous expression of the delivered ~~blood coagulation protein~~ Factor IX.
- 25.-27. (Cancelled)
28. (Currently Amended) The method of claim 1, wherein said cyclophosphamide is administered concomitantly with said ~~gene therapy~~ adeno-associated viral vector.
- 29.-42. (Canceled)
43. (New) The method of claim 1, wherein formation of said inhibitory antibodies is determined by Bethesda titers.